Genesis Healthcare, Inc. GENNQ
—
0.00
0.00
NaN
as of 24 Sep
- Market cap
- —
- P/E
- 0.0×
Follow GENNQ
| Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 13.67 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.01 | 0.04 | 0.02 | 0.01 | 0.07 |
P/FCF ratio |
0.17 | 0.00 | 2.85 | 0.55 | 22.50 |
P/Operating CF |
1.55 | (7.68) | 26.38 | 1.51 | 11.99 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.34 | 0.38 | 0.98 | 0.93 | 0.93 |
EV/EBITDA |
0.00 | 13.14 | 16.69 | 20.98 | 9.53 |
EV/Operating CF |
4.21 | (240.65) | 263.52 | 41.70 | 78.10 |
EV/FCF |
4.25 | (4.27) | 117.14 | 34.18 | 303.03 |
Quick Ratio |
0.19 | 0.63 | 0.83 | 0.91 | 1.08 |
Current Ratio |
0.23 | 0.77 | 0.96 | 1.05 | 1.23 |
Net Debt/EBITDA |
(3.32) | 11.80 | 16.28 | 20.65 | 8.82 |
Debt/Assets |
38.86% | 35.51% | 115.12% | 105.14% | 87.17% |
Debt/Equity |
(1.36) | (1.53) | (2.40) | (3.00) | (6.90) |
Asset Turnover |
0.90 | 1.02 | 1.10 | 1.02 | 0.97 |
Operating CF/Net income |
(5.35) | (0.49) | (0.08) | (0.21) | (1.07) |
Capex/Depreciation |
(0.03) | (3.22) | 0.10 | 0.04 | (0.20) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5.25% | (0.93%) | 12.63% | 48.04% | 9.49% | |
| (1.35%) | 0.33% | (5.20%) | (10.96%) | (1.08%) | |
ROIC |
(267.94%) | 1.09% | 1.58% | (7.21%) | 4.49% |
Return on Tangible Assets |
2.96% | 2.03% | (8.25%) | (16.76%) | (1.61%) |
Average Days of Receivables |
39.89 | 45.38 | 45.67 | 49.19 | 52.98 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
71.62% | 66.07% | 61.61% | 62.38% | 64.58% |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.05 | 0.05 | 0.11 |
Share Based Compensation of Revenue |
0.17% | 0.16% | 0.18% | 0.18% | 0.15% |
Graham Net Nets |
(81.12) | (27.94) | (45.58) | (69.03) | (13.75) |
Graham Number |
11.90 | 0.00 | 32.58 | 49.51 | 11.47 |
Earnings Yield |
(126.10%) | 7.32% | (197.46%) | (718.82%) | (16.33%) |
Free Cash Flow Yield |
581.72% | (229.47%) | 35.08% | 183.47% | 4.45% |
Revenue per Share |
34.92 | 42.56 | 49.27 | 57.04 | 63.78 |
Operating CF per Share |
2.82 | (0.07) | 0.18 | 1.28 | 0.76 |
Capex per Share |
(0.03) | (3.70) | 0.23 | 0.28 | (0.56) |
Free Cash Flow per Share |
2.79 | (3.76) | 0.41 | 1.56 | 0.20 |
Cash per Share |
2.70 | 1.00 | 1.29 | 0.97 | 1.06 |
Shareholders Equity per Share |
(10.39) | (10.09) | (20.24) | (17.83) | (8.12) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(10.39) | (10.09) | (20.24) | (17.83) | (8.12) |
Free Cash Flow |
312.32 | (403.75) | 41.81 | 146.93 | 17.62 |
Working Capital |
(2,975.58) | (242.32) | (36.59) | 40.71 | 201.43 |
Capital Expenditures |
(3.41) | (396.58) | 23.22 | 26.48 | (50.74) |
Net Current Asset Value |
(4,355.36) | (4,915.86) | (5,432.86) | (5,528.09) | (5,450.40) |
EV/EBIT |
0.00 | 212.72 | 70.93 | 0.00 | 17.64 |
Capex to Sales |
0.00 | 0.09 | 0.00 | 0.00 | 0.01 |
Net Profit Margin |
(1.51%) | 0.32% | (4.73%) | (10.77%) | (1.12%) |
Price to Operating Income |
0.00 | 21.70 | 1.73 | 0.00 | 1.31 |
| Other line items | |||||
Depreciation/Fixed assets |
0.11 | 0.13 | 0.08 | 0.18 | 0.07 |
Cash ROIC |
(93.18%) | (142.52%) | (95.83%) | (95.58%) | (83.98%) |
Accounts Receivable Turnover |
7.86 | 7.67 | 7.39 | 6.91 | 7.07 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
497.28 | 595.18 | 673.43 | 778.12 | 810.75 |
Average Payables |
224.87 | 236.59 | 260.21 | 272.13 | 246.21 |
Average Assets |
4,362.19 | 4,462.88 | 4,525.74 | 5,283.53 | 5,919.58 |
Average Common Equity |
(1,122.41) | (1,563.72) | (1,862.50) | (1,205.16) | (674.79) |
Columns are period end dates